Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression.

Mardiana S, Solomon BJ, Darcy PK, Beavis PA.

Sci Transl Med. 2019 Jun 5;11(495). pii: eaaw2293. doi: 10.1126/scitranslmed.aaw2293. Review.

PMID:
31167925
2.

Switching on the green light for chimeric antigen receptor T-cell therapy.

Mardiana S, Lai J, House IG, Beavis PA, Darcy PK.

Clin Transl Immunology. 2019 May 5;8(5):e1046. doi: 10.1002/cti2.1046. eCollection 2019. Review.

3.

Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM.

Clin Cancer Res. 2019 Feb 15;25(4):1437. doi: 10.1158/1078-0432.CCR-18-4264. No abstract available.

PMID:
30770496
4.

Antagonism of IAPs Enhances CAR T-cell Efficacy.

Michie J, Beavis PA, Freeman AJ, Vervoort SJ, Ramsbottom KM, Narasimhan V, Lelliott EJ, Lalaoui N, Ramsay RG, Johnstone RW, Silke J, Darcy PK, Voskoboinik I, Kearney CJ, Oliaro J.

Cancer Immunol Res. 2019 Feb;7(2):183-192. doi: 10.1158/2326-6066.CIR-18-0428. Epub 2019 Jan 16.

PMID:
30651288
5.

Targeting Adenosine Receptor Signaling in Cancer Immunotherapy.

Sek K, Mølck C, Stewart GD, Kats L, Darcy PK, Beavis PA.

Int J Mol Sci. 2018 Dec 2;19(12). pii: E3837. doi: 10.3390/ijms19123837. Review.

6.

Publisher Correction: Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis.

Savas P, Virassamy B, Ye C, Salim A, Mintoff CP, Caramia F, Salgado R, Byrne DJ, Teo ZL, Dushyanthen S, Byrne A, Wein L, Luen SJ, Poliness C, Nightingale SS, Skandarajah AS, Gyorki DE, Thornton CM, Beavis PA, Fox SB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Darcy PK, Speed TP, Mackay LK, Neeson PJ, Loi S.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0176-6.

PMID:
30135555
7.

Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3- Cell-Mediated Modulation of CD103+ Dendritic Cells.

Beavis PA, Henderson MA, Giuffrida L, Davenport AJ, Petley EV, House IG, Lai J, Sek K, Milenkovski N, John LB, Mardiana S, Slaney CY, Trapani JA, Loi S, Kershaw MH, Haynes NM, Darcy PK.

Cancer Immunol Res. 2018 Sep;6(9):1069-1081. doi: 10.1158/2326-6066.CIR-18-0291. Epub 2018 Jul 17.

PMID:
30018045
8.

Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis.

Savas P, Virassamy B, Ye C, Salim A, Mintoff CP, Caramia F, Salgado R, Byrne DJ, Teo ZL, Dushyanthen S, Byrne A, Wein L, Luen SJ, Poliness C, Nightingale SS, Skandarajah AS, Gyorki DE, Thornton CM, Beavis PA, Fox SB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Darcy PK, Speed TP, Mackay LK, Neeson PJ, Loi S.

Nat Med. 2018 Jul;24(7):986-993. doi: 10.1038/s41591-018-0078-7. Epub 2018 Jun 25. Erratum in: Nat Med. 2018 Dec;24(12):1941.

PMID:
29942092
9.

Tumor immune evasion arises through loss of TNF sensitivity.

Kearney CJ, Vervoort SJ, Hogg SJ, Ramsbottom KM, Freeman AJ, Lalaoui N, Pijpers L, Michie J, Brown KK, Knight DA, Sutton V, Beavis PA, Voskoboinik I, Darcy PK, Silke J, Trapani JA, Johnstone RW, Oliaro J.

Sci Immunol. 2018 May 18;3(23). pii: eaar3451. doi: 10.1126/sciimmunol.aar3451.

PMID:
29776993
10.

Tumor-derived exosomes modulate T cell function through transfer of RNA.

House IG, Petley EV, Beavis PA.

FEBS J. 2018 Mar;285(6):1030-1032. doi: 10.1111/febs.14413.

11.

Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity.

Davenport AJ, Cross RS, Watson KA, Liao Y, Shi W, Prince HM, Beavis PA, Trapani JA, Kershaw MH, Ritchie DS, Darcy PK, Neeson PJ, Jenkins MR.

Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):E2068-E2076. doi: 10.1073/pnas.1716266115. Epub 2018 Feb 12. Erratum in: Proc Natl Acad Sci U S A. 2019 May 28;116(22):11075-11076.

12.

T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma.

Hilmenyuk T, Ruckstuhl CA, Hayoz M, Berchtold C, Nuoffer JM, Solanki S, Keun HC, Beavis PA, Riether C, Ochsenbein AF.

Oncoimmunology. 2017 Sep 21;7(1):e1365997. doi: 10.1080/2162402X.2017.1365997. eCollection 2017.

13.

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer.

Dushyanthen S, Teo ZL, Caramia F, Savas P, Mintoff CP, Virassamy B, Henderson MA, Luen SJ, Mansour M, Kershaw MH, Trapani JA, Neeson PJ, Salgado R, McArthur GA, Balko JM, Beavis PA, Darcy PK, Loi S.

Nat Commun. 2017 Sep 19;8(1):606. doi: 10.1038/s41467-017-00728-9.

14.

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.

Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, Lam EYN, Henderson MA, Bell CC, Stolzenburg S, Gilan O, Bloor S, Noori T, Morgens DW, Bassik MC, Neeson PJ, Behren A, Darcy PK, Dawson SJ, Voskoboinik I, Trapani JA, Cebon J, Lehner PJ, Dawson MA.

Nature. 2017 Sep 7;549(7670):101-105. doi: 10.1038/nature23643. Epub 2017 Aug 16.

15.

A Novel Target Antigen for the Treatment of Acute Myeloid Leukemia by CAR T Cells.

Beavis PA, Sek K, Darcy PK.

Mol Ther. 2017 Sep 6;25(9):1997-1998. doi: 10.1016/j.ymthe.2017.07.001. Epub 2017 Jul 14. No abstract available.

16.

A novel combination strategy for effectively targeting cancer stem-like cells.

Beavis PA, Petley EV, Darcy PK.

Immunol Cell Biol. 2017 Aug;95(7):573-574. doi: 10.1038/icb.2017.39. Epub 2017 Jun 6. No abstract available.

PMID:
28529324
17.

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.

Hogg SJ, Vervoort SJ, Deswal S, Ott CJ, Li J, Cluse LA, Beavis PA, Darcy PK, Martin BP, Spencer A, Traunbauer AK, Sadovnik I, Bauer K, Valent P, Bradner JE, Zuber J, Shortt J, Johnstone RW.

Cell Rep. 2017 Feb 28;18(9):2162-2174. doi: 10.1016/j.celrep.2017.02.011.

18.

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy.

Beavis PA, Henderson MA, Giuffrida L, Mills JK, Sek K, Cross RS, Davenport AJ, John LB, Mardiana S, Slaney CY, Johnstone RW, Trapani JA, Stagg J, Loi S, Kats L, Gyorki D, Kershaw MH, Darcy PK.

J Clin Invest. 2017 Mar 1;127(3):929-941. doi: 10.1172/JCI89455. Epub 2017 Feb 6.

19.

A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.

Mardiana S, John LB, Henderson MA, Slaney CY, von Scheidt B, Giuffrida L, Davenport AJ, Trapani JA, Neeson PJ, Loi S, Haynes NM, Kershaw MH, Beavis PA, Darcy PK.

Cancer Res. 2017 Mar 15;77(6):1296-1309. doi: 10.1158/0008-5472.CAN-16-1831. Epub 2017 Jan 12.

20.

Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.

Slaney CY, von Scheidt B, Davenport AJ, Beavis PA, Westwood JA, Mardiana S, Tscharke DC, Ellis S, Prince HM, Trapani JA, Johnstone RW, Smyth MJ, Teng MW, Ali A, Yu Z, Rosenberg SA, Restifo NP, Neeson P, Darcy PK, Kershaw MH.

Clin Cancer Res. 2017 May 15;23(10):2478-2490. doi: 10.1158/1078-0432.CCR-16-1860. Epub 2016 Dec 13.

21.

Immunosuppressive activities of adenosine in cancer.

Allard B, Beavis PA, Darcy PK, Stagg J.

Curr Opin Pharmacol. 2016 Aug;29:7-16. doi: 10.1016/j.coph.2016.04.001. Epub 2016 May 19. Review.

PMID:
27209048
22.

Reprogramming the tumor microenvironment to enhance adoptive cellular therapy.

Beavis PA, Slaney CY, Kershaw MH, Gyorki D, Neeson PJ, Darcy PK.

Semin Immunol. 2016 Feb;28(1):64-72. doi: 10.1016/j.smim.2015.11.003. Epub 2015 Nov 25. Review.

PMID:
26611350
23.

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM.

Clin Cancer Res. 2016 Mar 15;22(6):1499-509. doi: 10.1158/1078-0432.CCR-15-1125. Epub 2015 Oct 29. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1437.

24.

CD73: A potential biomarker for anti-PD-1 therapy.

Beavis PA, Slaney CY, Milenkovski N, Henderson MA, Loi S, Stagg J, Kershaw MH, Darcy PK.

Oncoimmunology. 2015 May 5;4(11):e1046675. eCollection 2015 Nov.

25.

Relevance of tumor-infiltrating lymphocytes in breast cancer.

Dushyanthen S, Beavis PA, Savas P, Teo ZL, Zhou C, Mansour M, Darcy PK, Loi S.

BMC Med. 2015 Aug 24;13:202. doi: 10.1186/s12916-015-0431-3. Review.

26.

Cross-talk between tumors can affect responses to therapy.

Devaud C, John LB, Westwood JA, Yong CS, Beavis PA, Schwendener RA, Darcy PK, Kershaw MH.

Oncoimmunology. 2015 Jun 17;4(7):e975572. eCollection 2015 Jul.

27.

Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.

Beavis PA, Slaney CY, Kershaw MH, Neeson PJ, Darcy PK.

Immunotherapy. 2015;7(5):499-512. doi: 10.2217/imt.15.16. Review.

PMID:
26065476
28.

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses.

Beavis PA, Milenkovski N, Henderson MA, John LB, Allard B, Loi S, Kershaw MH, Stagg J, Darcy PK.

Cancer Immunol Res. 2015 May;3(5):506-17. doi: 10.1158/2326-6066.CIR-14-0211. Epub 2015 Feb 11.

29.

CD3bright signals on γδ T cells identify IL-17A-producing Vγ6Vδ1+ T cells.

Paget C, Chow MT, Gherardin NA, Beavis PA, Uldrich AP, Duret H, Hassane M, Souza-Fonseca-Guimaraes F, Mogilenko DA, Staumont-Sallé D, Escalante NK, Hill GR, Neeson P, Ritchie DS, Dombrowicz D, Mallevaey T, Trottein F, Belz GT, Godfrey DI, Smyth MJ.

Immunol Cell Biol. 2015 Feb;93(2):198-212. doi: 10.1038/icb.2014.94. Epub 2014 Nov 11.

30.

A2A blockade enhances anti-metastatic immune responses.

Beavis PA, Milenkovski N, Stagg J, Smyth MJ, Darcy PK.

Oncoimmunology. 2013 Dec 1;2(12):e26705. Epub 2013 Oct 22.

31.

Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.

Beavis PA, Divisekera U, Paget C, Chow MT, John LB, Devaud C, Dwyer K, Stagg J, Smyth MJ, Darcy PK.

Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14711-6. doi: 10.1073/pnas.1308209110. Epub 2013 Aug 20.

32.

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.

John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK.

Clin Cancer Res. 2013 Oct 15;19(20):5636-46. doi: 10.1158/1078-0432.CCR-13-0458. Epub 2013 Jul 19.

33.

CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.

Loi S, Pommey S, Haibe-Kains B, Beavis PA, Darcy PK, Smyth MJ, Stagg J.

Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11091-6. doi: 10.1073/pnas.1222251110. Epub 2013 Jun 17.

34.

CD73: a potent suppressor of antitumor immune responses.

Beavis PA, Stagg J, Darcy PK, Smyth MJ.

Trends Immunol. 2012 May;33(5):231-7. doi: 10.1016/j.it.2012.02.009. Epub 2012 Apr 7. Review.

PMID:
22487321
35.

CD73-deficient mice are resistant to carcinogenesis.

Stagg J, Beavis PA, Divisekera U, Liu MC, Möller A, Darcy PK, Smyth MJ.

Cancer Res. 2012 May 1;72(9):2190-6. doi: 10.1158/0008-5472.CAN-12-0420. Epub 2012 Mar 6.

36.

Resistance to regulatory T cell-mediated suppression in rheumatoid arthritis can be bypassed by ectopic foxp3 expression in pathogenic synovial T cells.

Beavis PA, Gregory B, Green P, Cribbs AP, Kennedy A, Amjadi P, Palfreeman AC, Feldmann M, Brennan FM.

Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16717-22. doi: 10.1073/pnas.1112722108. Epub 2011 Sep 16.

Supplemental Content

Loading ...
Support Center